# Feasibility of Adjacent Insulin Infusion and Continuous Glucose Monitoring via the Medtronic Combo-Set

David N. O'Neal, M.B.B.S., M.D., FRACP,<sup>1</sup> Sumona Adhya, M.S.,<sup>2</sup> Alicia Jenkins, M.B.B.S., M.D., FRACP,<sup>1</sup> Glenn Ward, M.B.B.S., Ph.D., FRACP,<sup>1</sup> John B. Welsh, M.D., Ph.D.,<sup>2</sup> and Gayane Voskanyan, Ph.D.<sup>2</sup>

## Abstract

### Background:

Subcutaneously infused insulin may interfere with the function of nearby glucose-sensing electrodes and *vice versa*. The prototype of the Combo-Set device (Medtronic) incorporates a subcutaneous insulin delivery catheter and continuous glucose monitoring (CGM) sensor assembled on the same platform and separated by 11 mm. We aim to evaluate Combo-Set's insulin delivery and glucose-sensing functions.

### Methods:

Ten subjects with type 1 diabetes wore a Combo-Set and a Sof-Sensor inserted subcutaneously in contralateral abdominal areas connected to *i*Pro recorders (Medtronic) for  $53.25 \pm 0.75$  h (mean  $\pm$  standard deviation). The Combo-Set delivered insulin diluent except during meal tests on days 1 and 3 when insulin lispro was delivered as a meal bolus and postmeal basal. Venous plasma samples were collected at the following time points from meal start: 0, 30, 60, 120, and 180 min for insulin measurements. The accuracy of the Combo-Set sensors was evaluated and compared with that of the Sof-Sensor, with each referenced against capillary glucose values (Contour Link Meter, Bayer).

### Results:

Accuracy of the Combo-Set sensor was comparable to that of the Sof-Sensor. Clarke error grid analysis showed that 97% of Combo-Set and 93% of Sof-Sensor values were in the A+B regions (p = .20, not significant). The Combo-Set showed the expected postbolus peak insulin time (67 ± 9 min, mean ± standard error). One "no delivery" alarm occurred during the 21 patient days of use.

### Conclusion:

A device providing for simultaneous adjacent placement of an insulin infusion catheter and a CGM sensor is feasible and functions within acceptable limits. The low "no delivery" alarm rate was similar to that of other infusion sets.

J Diabetes Sci Technol 2013;7(2):381–388

Author Affiliations: <sup>1</sup>Department of Medicine, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria, Australia; and <sup>2</sup>Medtronic Inc., Northridge, California

Abbreviations: (CGM) continuous glucose monitoring, (CSII) continuous subcutaneous insulin infusion, (CTU) clinical trial unit, (ISF) interstitial fluid, (MARD) mean absolute relative difference, (RT-CGM) real-time continuous glucose monitoring, (SD) standard deviation, (T1DM) type 1 diabetes mellitus

Keywords: accuracy, colocalization, continuous glucose monitoring, glucose sensing, insulin delivery

**Corresponding Author:** David O'Neal, M.B.B.S., M.D., FRACP, University of Melbourne, Department of Medicine, St. Vincent's Hospital, 4th Floor Clinical Sciences Building, Cnr of Princess and Regent Sts., Fitzroy 3065, Australia; email address <u>dno@unimelb.edu.au</u>